A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer
The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.
Inclusion Criteria:
Exclusion Criteria:
Buenos Aires, Buenos Aires C1181ACH, Argentina
Buenos Aires, Buenos Aires C1280AEB, Argentina
Buenos Aires, Buenos Aires C1426ANZ, Argentina
Caba, Buenos Aires 1417, Argentina
Capital Federal, Buenos Aires 1425, Argentina
Capital Federal, Buenos Aires 1426, Argentina
Capital Federal, Buenos Aires C1405BCJ, Argentina
Cordaba, 5000, Argentina
Abbottsford, British Columbia V2S 3N5, Canada
Df, Mexico City 06720, Mexico
Timisoara, Timis, 300239, Romania
Essex, Essex CO3 3NB, United Kingdom